PMS Forum 1 MedDRAの基礎知識 出典: MSSO-DI-6225-7.1.0 2004 Northrop Grumman Corporation. PMS担当者研修テキスト (7) PMS フォーラム作 成 スライドは英語のままですが、ノート部に訳がついて います。 保存後確認ください。

Slides:



Advertisements
Similar presentations
Mary Ellen Turner MD, MPH Vice-President
Advertisements

The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.
Introduction to MedDRA® (Medical Dictionary for Regulatory Activities)
Tips to a Successful Monitoring Visit
Adverse Events and Serious Adverse Events
Safety Reporting IN Clinical Trials
Data Quality, Coding, and MedDRA MedDRA ® trademark is owned by IFPMA on behalf of ICH.
Data Quality, Coding, and MedDRA ® MedDRA® is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
HIBBs is a program of the Global Health Informatics Partnership Introduction to Form Design Regional East African Centre for Health Informatics (REACH-INFORMATICS)
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
An introduction to CDISC and CDASH Bring on the Standards! Emmanuelle Denis M.Sc., MICR Global Health Clinical Trials Research Programme.
Extraction of Adverse Drug Effects from Clinical Records E. ARAMAKI* Ph.D., Y. MIURA **, M. TONOIKE ** Ph.D., T. OHKUMA ** Ph.D., H. MASHUICHI ** Ph.D.,K.WAKI.
MedDRA® Overview NCI Vocabulary and Common Data Elements Workspace
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Justina A. Molzon, MS Pharm, JD
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Pharmacovigilance obligations of the Pharmaceutical companies in India
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
 Definitions  Goals of automation in pharmacy  Advantages/disadvantages of automation  Application of automation to the medication use process  Clinical.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes.
How To Design a Clinical Trial
FDA Regulatory and Compliance Symposium
Introduction.
Minimum requirements for Pharmacovigilance in countries.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
Data Quality, Coding, and MedDRA. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Finding Content in SNOMED CT Jo Oakes – Knowledge & Information Manager.
1 Division of Pharmacoepidemiology and Pharmacovigilance AEMPS Dolores Montero Corominas 20 November Management of the Adverse drug reaction (ADR),
Clinical Trials.

Data Quality, Coding, and MedDRA
The Information Professional’s Role in Product Safety
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
EudraVigilance.
DIA Clinical Safety and Pharmacovigilance Community
Administering Informed Consent Issues for Discussion
Pharmacovigilance in clinical trials
HOW TO FULFILL STATUTORY REQUIREMENTS ON PRODUCT RELATED HEALTH INFORMATION Samina Qureshi, M.D. PSI INTERNATIONAL Inc.
9. Introduction to signal detection
Combination products The paradigm shift
SERIOUS ADVERSE EVENTS REPORTING
Utilizing FDA Standard Terminology
Fundamentals of Electronic Submissions and eCTD
Patient Involvement in the Development and Safe Use of
Model Enhanced Classification of Serious Adverse Events
Towards International Harmonized Nomenclature for Medical Devices
Adverse Event Reporting _____________________________
Dr Tim England TICH-2 SAE adjudicator
Serious Adverse Event Reconciliation
Presentation transcript:

PMS Forum 1 MedDRAの基礎知識 出典: MSSO-DI Northrop Grumman Corporation. PMS担当者研修テキスト (7) PMS フォーラム作 成 スライドは英語のままですが、ノート部に訳がついて います。 保存後確認ください。

PMS Forum Data Quality, Coding and MedDRA ® MedDRA ® is a registered trademark of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA)

PMS Forum 3 Course Overview To provide an understanding of: Importance of good quality data How clinical data are coded MedDRA background Coding examples Benefits of good quality data

PMS Forum 4 Data Quality and Clinical Trials Highly regulated environment with increasing emphasis on safety surveillance and data quality EU Clinical Trials Directive effective May 1, 2004 –Key provisions include conduct of clinical trials & pharmacovigilance –Notification of suspected unexpected serious adverse reactions (SUSARs) Similar FDA regulations governing pre- & postmarketing safety reporting Objective is global harmonization

PMS Forum 5 What is meant by good quality data? Complete Accurate Diagnosis supported by appropriate investigations Causality assessment for adverse events

PMS Forum 6 Quality of Input = Quality of Output IN OUT

PMS Forum 7 Coding of Clinical Trial Data Most data entered on Case Report Forms are “coded” in some form Facilitates storage, retrieval, analysis and presentation of data Some coding is performed by investigators at point of data entry –e.g. numeric codes for severity of adverse event: 1= mild, 2= moderate etc. Other coding of text data is performed by the sponsor company after data collection Accuracy of initial coding determines accuracy of analysis

PMS Forum 8 MedDRA Background

PMS Forum 9 What is MedDRA? Med = Medical D = Dictionary for R = Regulatory A = Activities

PMS Forum 10 MedDRA Definition MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre- marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.

PMS Forum 11 Key Features of MedDRA Standardized terminology International scope - translated into several languages, including Spanish, French and Japanese Managed by Maintenance and Support Services Organization (MSSO) and updated bi-annually with input from User Groups (company subscribers)

PMS Forum 12 Key Features of MedDRA (cont) Structure facilitates data analysis and reporting and electronic communication Large terminology with > 60,000 terms at lowest level - allows greater specificity Approx. 16,000 Preferred Terms, each representing a unique medical concept Typically used for coding adverse events, signs and symptoms, procedures, investigations, indications and medical and social histories MedDRA is not a drug dictionary

PMS Forum 13 Regulatory Status of Mandate US FDA –MedDRA used in FDA’s internal adverse event database –Proposed Rule for Safety Reporting Requirements (2003): FDA proposes to use MedDRA for postmarketing safety reports European Union –All reports (electronic) – January 2003 –EudraCT (European Clinical Trials Database) requires MedDRA –SUSARs (Suspected Unexpected Serious Adverse Reactions) require MedDRA Japanese Ministry of Health, Labour and Welfare –Electronic reports mandatory from October 2003 –MedDRA to be used in Periodic Infection & Safety Reports from April 2004

PMS Forum 14 Regulatory Status of Mandate (cont) Common Technical Document –A standard format for new drug and biologic product applications to regulatory authorities –Includes summary documents and reports from individual clinical trials –MedDRA is the recommended terminology for describing adverse events, both serious and non- serious –CTD format is mandatory in EU and Japan and is highly recommended in the US from July 2003

PMS Forum 15 Diseases Diagnoses Signs Symptoms Therapeutic indications Investigation names & qualitative results Medical & surgical procedures Medical, social, family history Drug product terms Equipment, device, diagnostic product terms Device failure terms Clinical trial study design terms Patient demographic terms Population-level qualifiers Numerical values for results Severity descriptors OUT Terms from: COSTART © WHO-ART © HARTS © IN Scope of MedDRA

PMS Forum 16 Making the Most of MedDRA To take advantage of MedDRA’s richness and specificity, the source data should be –clear –concise –complete –accurate General principles apply to all clinical data

PMS Forum 17 Problems with coding data Appropriate coding requires clear initial data A meaning that is clear to the investigator at the point of data entry may be unclear to the sponsor at the point of data coding Example: Ambiguous information –Congestion (nasal, liver, sinus, pulmonary?) –Cramp (muscle, menstrual, abdominal?) –Pain (pain where?)

PMS Forum 18 Problems with coding data (cont) Example: Ambiguous abbreviations –MI (myocardial infarction or mitral incompetence?) –GU pain (gastric ulcer pain or genito-urinary pain?) –Decreased BS (breath sounds, bowel sounds or blood sugar?) –COLD (feeling cold, common cold or chronic obstructive lung disease?) Exercise caution with abbreviations that could be misinterpreted ECG, URI, HIV are examples of standard abbreviations

PMS Forum 19 Problems with coding data (cont) Example: Vague information –Patient felt “fuzzy”, “weird”, “experienced every adverse event” Try to use accepted medical terminology Example: Non-specific information –“Left wrist edema” (coded as Peripheral edema) –More specific - “Injection site edema left wrist” (coded as Injection site edema)

PMS Forum 20 Problems with coding data (cont) Death is an outcome and is not usually considered to be an adverse event Provide details of cause of death if known Example: –“Death due to myocardial infarction” – Myocardial infarction is coded and death is captured as the outcome

PMS Forum 21 Problems with coding data (cont) Example: Ambiguous laboratory data –“Glucose of 40” –(Source of specimen - blood, urine, CSF? What units?) –Would have to code as “glucose abnormal” if additional clarification is not obtained Example: Conflicting laboratory data –“Hyperkalemia with serum potassium of 1.6 mEq/L” –Would have to code as “serum potassium abnormal” If using numeric values, provide units and reference range. Be specific about specimen source and diagnostic result/clinical diagnosis

PMS Forum 22 Problems with coding data (cont) Example: Combination terms –Diarrhea, nausea and vomiting Try to avoid combination terms - these will have to be split into 3 individual terms Diarrhea Nausea Vomiting

PMS Forum 23 Reporting a specific diagnosis Where possible, report the most important medical event or specific diagnosis rather than individual signs and symptoms Can provide provisional diagnosis e.g. “possible”, “presumed”, “rule out” Accuracy is important in preventing dilution of safety signals or generating false signals SIGNS & SYMPTOMSDIAGNOSIS Chest pain, dyspnea, diaphoresis, ECG changes Myocardial infarction

PMS Forum 24 Safety signals Accuracy in diagnosis is important for detection and evaluation of safety signals Events of importance in drug safety surveillance include: –QTc prolongation –Hepatotoxicity –Stevens Johnson syndrome –Convulsions –Rhabdomyolysis

PMS Forum 25 Generating Quality Data Clear Concise Complete Accurate Be specific if necessary - MedDRA can handle multiple specific medical concepts: –Headache - more than 50 types, including cluster, sinus, migraine, lumbar puncture headache –Organisms - down to species level e.g. Staphylococcus aureus

PMS Forum 26 Miscellaneous Verbatims: Coding Challenges Recurrent fatal stroke LK RTCTL UNSP XTRNDL ORG Hears New Age music when furnace turns on Funk exacerbated Normally normal after drinking coffee Went to hell Patient is intermittently tiresome Infection in first finger of the right foot Fireballs in uterus Blast (menopause) Flintstone feet Barely visible posterior

Company-specific conventions Insert slides as required to cover company’s specific data collection and recording conventions Could include instructions on how to complete data fields for adverse events, medical history etc. on paper or electronic CRFs Could include general principles of how to record text-based information as well as specific instructions for particular therapeutic areas

PMS Forum 28 Benefits of Quality Data Fewer queries for investigator and sponsor

PMS Forum 29 Benefits of Quality Data (cont) Accurate and timely information on issues that affect conduct of clinical trial and affect patient safety Improved communication among sponsors, investigators and regulatory agencies about medicinal products –Aids in safety signal detection and evaluation –Ensures accuracy of information about the product including investigators’ brochures and prescribing information –Benefits medical professionals –Benefits patients

PMS Forum 30 Quality Data INOUT

PMS Forum 31 Course Evaluation Thank you for taking this course Please take the time to fill out the evaluation form Thank you for your feedback

PMS Forum 32 MSSO Contacts Mail MSSO VAR1/MSSO Sunset Hills Road Reston, VA USA Telephone –Toll-free Worldwide (AT&T) Web page –

PMS Forum 33 Acknowledgements MedDRA ® is a registered trademark of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) COSTART Thesaurus Fifth Edition Copyright  1995 US Food and Drug Administration (FDA) Hoechst Adverse Reaction Terminology System (HARTS) © 1992 Aventis Pharma WHO Adverse Reaction Terminology (WHO-ART), Copyright  World Health Organization Collaborating Centre for International Drug Monitoring